Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
PLoS One. 2024 Oct 3;19(10):e0306705. doi: 10.1371/journal.pone.0306705. eCollection 2024.
The six most common missense mutations in the DNA binding domain of p53 are known as "hot spots" and include two of the most frequently occurring p53 mutations (p53-R175H and p53-R273H). p53 stability and function are regulated by various post-translational modifications such as phosphorylation, acetylation, sumoylation, methylation, and interactions with other proteins including plakoglobin. Previously, using various carcinoma cell lines we showed that plakoglobin interacted with wild-type and several endogenous p53 mutants (e.g., R280K, R273H, S241F, S215R, R175H) and restored their tumor suppressor activities in vitro. Since mutant p53 function is both mutant-specific and cell context-dependent, we sought herein, to determine if plakoglobin tumor suppressive effects on exogenously expressed p53-R273H and p53-R175H mutants are similarly maintained under the same genetic background using the p53-null and plakoglobin-deficient H1299 cell line. Functional assays were performed to assess colony formation, migration, and invasion while immunoblotting and qPCR were used to examine the subcellular distribution and expression of specific proteins and genes that are typically regulated by or regulate p53 function and are altered in mutant p53-expressing cell lines and tumors. We show that though, plakoglobin interacted with both p53-R273H and p53-R175H mutants, it had a differential effect on the transcription and subcellular distribution of their gene targets and their overall oncogenic properties in vitro. Notably, we found that plakoglobin's tumor suppressive effects were significantly stronger in p53-R175H expressing cells compared to p53-R273H cells. Together, our results indicate that exploring plakoglobin interactions with p53-R175H may be useful for the development of cancer therapeutics focused on the restoration of p53 function.
p53 基因 DNA 结合域的六个最常见的错义突变被称为“热点”,其中包括两种最常见的 p53 突变(p53-R175H 和 p53-R273H)。p53 的稳定性和功能受到各种翻译后修饰的调节,如磷酸化、乙酰化、SUMO 化、甲基化,以及与其他蛋白质的相互作用,包括桥粒斑蛋白。以前,我们使用各种癌细胞系表明,桥粒斑蛋白与野生型和几种内源性 p53 突变体(例如 R280K、R273H、S241F、S215R、R175H)相互作用,并在体外恢复了它们的肿瘤抑制活性。由于突变型 p53 的功能既具有突变特异性又具有细胞背景依赖性,因此我们在此寻求确定,如果桥粒斑蛋白对表达外源 p53-R273H 和 p53-R175H 突变体的肿瘤抑制作用在具有相同遗传背景的情况下是否类似地维持,使用 p53 缺失和桥粒斑蛋白缺陷的 H1299 细胞系。进行功能测定以评估集落形成、迁移和侵袭,同时进行免疫印迹和 qPCR 以检查特定蛋白质和基因的亚细胞分布,这些蛋白质和基因通常受 p53 功能调节或调节,并且在突变型 p53 表达的细胞系和肿瘤中发生改变。我们表明,尽管桥粒斑蛋白与 p53-R273H 和 p53-R175H 突变体相互作用,但它对其基因靶标的转录和亚细胞分布及其整体致癌特性具有不同的影响在体外。值得注意的是,我们发现桥粒斑蛋白在 p53-R175H 表达细胞中的肿瘤抑制作用明显强于 p53-R273H 细胞。总之,我们的结果表明,探索桥粒斑蛋白与 p53-R175H 的相互作用可能有助于开发针对 p53 功能恢复的癌症治疗方法。